ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

DSA Monitoring in Kidney Transplant Recipients

F. Pean,1 M. Cooper,1 J. Verbesey,1 A. Gilbert,1 B. Javaid,1 R. Mohammed,1 O. Timofeeva,2 J. Moore,1 K. Cruz,1 R. Ghasemian,1 T. Fishbein,1 M. Grafals.1

1Medstar Georgetown Transplant Institute, Georgetown University, Washington, DC
2Clinical Laboratory and Histocompatibility, Georgetown University, Washington, DC.

Meeting: 2015 American Transplant Congress

Abstract number: A292

Keywords: Antibodies, Graft failure

Session Information

Session Name: Poster Session A: Late Breaking

Session Type: Poster Session

Date: Saturday, May 2, 2015

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Exhibit Hall E

Introduction: The development of DSA monitoring is a new technique to detect antibodies in kidney transplant recipients. Data has shown that development of DSA post kidney transplantation is associated with worst outcomes. Methods: We began performing DSA monitoring protocol on October 26, 2012. This analysis includes patients up to January 4, 2014 and one year of follow up. Results: 199 kidney transplant were performed at our transplant center during this period of time and 167 patients completed the DSA monitoring protocol. There was a 11.9% rate of dnDSA. Of the patients that developed dnDSA, 20% were class I, 60% were class II and 20% were both class I and II. 75% of patients developed either cellular or humoral rejection and 35% of patients lost their graft. Conclusions: The one year rejection and graft loss rate after the development of dnDSA is much higher than the national average. Therefore treatment protocols for dnDSA need to be established and implemented.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Pean F, Cooper M, Verbesey J, Gilbert A, Javaid B, Mohammed R, Timofeeva O, Moore J, Cruz K, Ghasemian R, Fishbein T, Grafals M. DSA Monitoring in Kidney Transplant Recipients [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/dsa-monitoring-in-kidney-transplant-recipients/. Accessed May 11, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences